For the quarter ending 2026-03-31, GOVX had -$1,813,979 decrease in cash & cash equivalents over the period. -$3,537,721 in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -5,261,921 | -4,418,423 | -6,318,914 | -10,727,434 |
| Depreciation and amortization expense | 12,076 | 18,230 | 16,802 | 33,724 |
| Stock-based compensation expense | 219,317 | 252,124 | 277,546 | 585,484 |
| Government contract receivable | 0 | 0 | -532,771 | -126,638 |
| Prepaid expenses and other current assets | -1,072,281 | 674,826 | -664 | -259,618 |
| Other assets | - | -43,560 | 15,937 | 0 |
| Accounts payable and accrued expenses | 420,526 | -182,441 | -705,047 | -578,108 |
| Total adjustments | 1,724,200 | -543,353 | 106,799 | 427,356 |
| Net cash used in operating activities | -3,537,721 | -4,961,776 | -6,212,115 | -10,300,078 |
| Purchase of equipment | 0 | 0 | 0 | 27,612 |
| Net cash used in investing activities | 0 | 0 | 0 | -27,612 |
| Net proceeds from issuance of notes payable related parties | - | 0 | 0 | 0 |
| Repayment of notes payable related parties | - | 0 | 0 | - |
| Net proceeds from sale of common stock and warrants | 1,718,901 | 3,038,520 | 7,971,250 | 7,914,402 |
| Net proceeds from warrant exercises | 4,841 | 0 | 156,000 | 209 |
| Net cash provided by financing activities | 1,723,742 | 3,038,520 | 8,127,250 | 7,914,611 |
| Net increase (decrease) in cash and cash equivalents | -1,813,979 | -1,923,256 | 1,915,135 | -2,413,079 |
| Cash and cash equivalents at beginning of period | 3,085,741 | 5,008,997 | 5,506,941 | - |
| Cash and cash equivalents at end of period | 1,271,762 | 3,085,741 | 5,008,997 | - |
GeoVax Labs, Inc. (GOVX)
GeoVax Labs, Inc. (GOVX)